Regression of severe heart failure after combined left ventricular assist device placement and sleeve gastrectomy

Sriram S. Nathan¹, Pouya Iranmanesh², Igor D. Gregoric³, Mehmet H. Akay¹, Sachin Kumar¹, Bindu H. Akkanti³, Ismael A. Salas de Armas¹, Manish Patel¹, Melissa M. Felinski², Shinil K. Shah², Kulvinder S. Bajwa² and Biswajit Kar¹*

¹Department of Advanced Cardiopulmonary Therapies and Transplantation, UTHealth, 6400 Fannin St, Suite 2350, Houston, TX 77030, USA; ²Department of Surgery, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA; ³Division of Critical Care Medicine, Department of Medicine, UTHealth, Houston, TX, USA

Abstract

Patients who suffer morbid obesity and heart failure (HF) present unique challenges. Two cases are described where concomitant use of laparoscopic sleeve gastrectomy (LSG) and left ventricular assist device (LVAD) placement enabled myocardial recovery and weight loss resulting in explantation. A 29-year-old male patient with a body mass index (BMI) of 59 kg/m² and severe HF with a left ventricular ejection fraction (LVEF) of 20–25% underwent concomitant LSG and LVAD placement. Sixteen months after surgery, his BMI was reduced to 34 kg/m² and his LVEF improved to 50–55%. A second 41-year-old male patient with a BMI of 44.8 kg/m² with severe HF underwent the same procedures. Twenty-four months later, his BMI was 31.1 kg/m² and his LVEF was 50–55%. In both cases, the LVAD was successfully explanted and patients remain asymptomatic. HF teams should consult and collaborate with bariatric experts to determine if LSG may improve the outcomes of their HF patients.

Keywords Gastric sleeve; Body mass index; Left ventricular assist device; Mechanical circulatory support; Obesity

Received: 9 June 2020; Revised: 3 December 2020; Accepted: 15 December 2020

*Correspondence to: Biswajit Kar, Department of Advanced Cardiopulmonary Therapies and Transplantation, Center for Advanced Heart Failure, The University of Texas Health Science Center at Houston, 6400 Fannin St, Suite 2350 Houston, TX 77030, USA. Email: biswajit.kar@uth.tmc.edu

Sriram S. Nathan and Pouya Iranmanesh share co-first authorship.

Introduction

In the USA, 39.8% of the adult population has a body mass index (BMI) > 30 kg/m² and 15.4% are considered to have morbid obesity (BMI > 40 kg/m²).¹ Excess weight and excess body fat result in numerous obesity-related comorbidities that affect the cardiovascular, musculoskeletal and respiratory systems.²,³ Numerous studies have shown the efficacy of bariatric surgery for the treatment of morbid obesity and its related comorbidities.⁴–⁹

Heart failure (HF) is typically progressive, and in advanced cases, patients may require a left ventricular (LV) assist device (LVAD) or cardiac transplantation. Bariatric surgery has been shown to improve cardiac function in patients with HF,¹⁰–¹² but its potential to significantly improve or normalize LV ejection fraction (LVEF) is debated. We present two patients with morbid obesity and advanced HF who significantly improved after concomitant laparoscopic sleeve gastrectomy (LSG) and LVAD placement and resulted in explantation of the LVADs.

Case report

Patient 1

A 29-year-old man with morbid obesity (BMI 59.05 kg/m²), asthma, and hypertension was admitted to an outside facility with worsening dyspnoea (Table 1). The hypertension was managed by angiotensin-converting enzyme inhibitors and beta-blocker as a part of guideline-directed medical therapy for his chronic systolic HF. Our institution uses clinical symptoms, laboratory results, and echocardiograms to diagnose HF per standard guideline. The modified Simpson method
was utilized for assessment of LV systolic function, which is a standard method for evaluation of ejection fraction in patients.

An echocardiogram revealed dilated cardiac chambers and severe reduction in LV systolic function with an LVEF of 20–25% (Table 2). Extensive evaluation including diagnostic coronary angiography revealed no precipitating or reversible cause of HF. In view of worsening symptoms despite optimal medical therapy, he was transferred to our facility for advanced therapy options.

Invasive haemodynamics revealed advanced HF. The patient was reviewed by the medical review board and approved for an LVAD. Given the morbid obesity, a concomitant LSG was performed in the hope that with weight loss, the patient will eventually be a heart transplant candidate. The patient received a Heartmate II™ (Thoratec Corporation, Pleasanton, CA) with concomitant LSG. Total operative time was 6 h and 58 min. Patient was extubated on post-operative Day 2 and had an uneventful recovery. He was discharged home on post-operative Day 11. Standard guideline therapy was continued for HF and the up-titrations of medication were based on patient’s haemodynamics and symptoms.

After 10 months, a repeat echocardiogram revealed a normal LV systolic function (LVEF = 50–55%). He had lost 57.8 kg and had a BMI of 35.6 kg/m². Repeat echocardiogram at approximately 13 months post-op revealed continued normalization of systolic function. Given the sustained myocardial recovery, tolerability of guideline-directed medical therapy

| Table 1 Baseline characteristics of patients |
|-------------------------------------------|
| Patient 1 | Patient 2 |
| Age (years) | 29 | 41 |
| Gender | Male | Male |
| Initial body mass index (kg/m²) | 59.0 | 44.8 |
| Excess body weight (kg) | 113.9 | 61.0 |
| Comorbidities | | |
| Hypertension | Yes | Yes |
| Obstructive sleep apnoea | No | Yes |
| Chronic kidney disease | No | Yes |
| Diabetes mellitus type II | No | No |
| Hyperlipidaemia | No | No |

| Table 2 Echocardiogram data for patients |
|-----------------------------------------|
| Patient 1 | Patient 2 |
| Just prior to LVAD/LSG procedure | Just prior to explantation procedure | Within 1 month of explantation |
| LVEF (%) | 25 | 50 | 54 |
| LV dilation | Severe | Normal | Normal |
| LVIDd/LVIDs (cm) | 6.8/6.0 | 5.4/3.9 | 5.9/4.3 |
| LA dilation | Severe | Normal | Normal |
| LA diameter (cm) | 4.1 | 4.3 | 4.3 |
| LA volume (ml) | 74.0 | 93.1 | 76.9 |
| LV hypertrophy | Severe, concentric | None | None |
| IVSd (cm) | 1.4 | 1.2 | 1.2 |
| LVPWd (cm) | 1.5 | 1.1 | 1.2 |
| RVSP (mmHg) | 35 | Cannot be calculated; No TR noted |
| RVSP (TR) (mmHg) | 30 | |
| RA pressure (mmHg) | 5 | |

| Patient 2 | Patient 2 |
| Just prior to LVAD/LSG procedure | Just prior to explantation procedure | Within 1 month of explantation | 1 year follow-up appointment |
| LVEF (%) | 16 | 54 | 59 | 45 |
| LV dilation | Moderate | Normal | Normal | Mild |
| LVIDd/LVIDs (cm) | 7.3/6.9 | 4.7/3.4 | 47/3.2 | 5.3/4.1 |
| LA dilation | Severe | Mild | Mild | Moderate |
| LA diameter (cm) | 5.4 | 3.5 | 4.2 | 4.2 |
| LA volume (ml) | 107 | 67.8 | 64.2 | 88.3 |
| LV hypertrophy | None | None | None | None |
| IVSd (cm) | 1.04 | 1.1 cm | 0.8 cm | 0.9 cm |
| LVPWd (cm) | 1.04 | 1.0 cm | 0.8 cm | 0.9 cm |
| RVSP (mmHg) | 36 | 28 | 33 | IVC could not be visualized |
| RVSP (TR) (mmHg) | 33 | 18 | 30 | |
| RA pressure (mmHg) | 3 | 10 | 3 | |

IVSd, interventricular septal end diastole; LA, left atrial; LSG, laparoscopic sleeve gastrectomy; LV, left ventricular; LVAD, left ventricular assist device; LVIDd, left ventricular internal diameter end diastole; LVIDs, left ventricular internal diameter end systole; LVPWd, left ventricular posterior wall thickness at end diastole; RA, right atrial; RVSP, right ventricular systolic pressure; TR, tricuspid regurgitation. The left ventricular ejection fraction was measured by the modified Simpson’s method. All other measurements were recorded using standard 2D methods.
for HF, he underwent echocardiographic evaluation at lower pump speed, which revealed continued normalized LV function. The decision was made to proceed with the LVAD explantation at approximately 16 months post-surgery. At that time, his BMI was 34.44 kg/m². At the last follow-up (approximately 5 months after explantation), the patient was doing well. His BMI was 35.24 kg/m² (total weight loss 74.8 kg).

**Patient 2**

A 41-year-old male patient with chronic systolic HF, hypertension, obstructive sleep apnoea, morbid obesity (BMI 44 kg/m²), and stage 2 chronic kidney disease was admitted to an outside hospital with worsening dyspnoea and New York Heart Association class 4 symptoms (Table 1). The hypotension was managed by angiotensin-converting enzyme inhibitors and beta-blocker as a part of guideline-directed medical therapy for his chronic systolic HF. An echocardiogram revealed severe LV systolic dysfunction (LVEF = 20–25%) and severe mitral regurgitation (Table 2). Haemodynamics indicated cardiogenic shock. Extensive evaluation including diagnostic coronary angiography revealed no precipitating or reversible cause of HF. The patient was reviewed by the medical review board and approved for a Heartmate II™. Given the morbid obesity, a concurrent LSG along with the LVAD implant was carried out. Total operative time was 7 h and 20 min. The patient was extubated on post-operative Day 1. Patient was discharged home on post-operative Day 16. Standard guideline therapy was continued for HF and the up-titrations of medication were based on patient’s haemodynamics and symptoms.

After 13 months, a repeat echocardiogram demonstrated normal LV size and systolic function (LVEF = 50–55%). The up-titrating of the patient’s HF therapy was at maximum tolerated doses (carvedilol 25 mg/twice per day; sacubitril/valsartan 24/26 mg/once per day; and aldaclone 12.5 mg/once per day). Given the myocardial recovery, he underwent LVAD explantation at approximately 24 months post-surgery. At that time, his BMI was 31.1 kg/m² (total weight loss 30.7 kg).

**Discussion**

This study describes two cases of advanced HF with morbid obesity and severe LV systolic dysfunction who underwent concomitant LSG and LVAD placement. Sixteen and 24 months post-op, both patients had a normalized LVEF (50–55%) and complete resolution of their HF-related symptoms. Their BMIs were below 35, and both successfully underwent LVAD explantation. The improvement in LVEF for these two patients (25–30%) was significantly higher than patients reported in previously published studies10–18 and obviated the need for cardiac transplantation.

Patients with obesity have an overall twofold risk of developing HF as compared with the normal population, with an increased risk of 5% in men and 7% in women for each increment of 1 kg/m² in BMI.19 Research indicates that obesity leads to heart disease through several direct and indirect pathways. Excess body fat results in myocardial accumulation of triglycerides,20 and this accumulation causes a chronic, systemic inflammatory response with an increased production of cytokines and acute-phase proteins.21 These two mechanisms can directly lead to myocardial fibrosis.20,21 On the other hand, obesity-related comorbidities indirectly affect cardiac function. Hypertension increases LV afterload, which may cause left cardiac hypertrophy.22 Dyslipidaemia and diabetes mellitus promote atherosclerosis, which increases the risk of ischaemic cardiomyopathy.23 Insulin resistance decreases myocardial contractility and potentiates the negative impact of hypertension on cardiac function by activating the renin–angiotensin–aldosterone system.24,25 Obstructive sleep apnoea syndrome causes hypoxaemia, hypercapnia, and oxidative stress with subsequent sympathetic activation and vascular inflammation.26 These various mechanisms may result in arrhythmias, systolic/diastolic dysfunctions, and ultimately HF. Due to the multifactorial cause, innovative methods are needed to treat obesity in the HF population.

Because the prevalence and severity of obesity have been constantly growing in the USA in the past years,4 a concomitant rise in the number of patients with obesity and HF is expected. The positive impact of bariatric surgery on HF was described in the 1970s by Backman et al.27 and has been supported by other recent articles.10–13,15,16,18 A number of physiological mechanisms that positively influence cardiovascular function among patients who undergo bariatric surgery have been identified.11,28,29 They include, among others, favourable changes in left atrial and ventricular mass and shape, abolition of high output state, and improvement of cardiovascular risk factors such as hypertension, diabetes, and hyperlipidaemia. Several recent studies advocated for concomitant bariatric surgery and LVAD placement as a bridge to cardiac transplantation for selected patients with obesity-related HF.13–15,17,18 LSG, as a relatively straightforward procedure without intestinal anastomosis, has a safer long-term risk profile compared with other bariatric procedures such as Roux-en-Y gastric bypass or biliopancreatic diversion.30–33 Therefore, it has emerged as the procedure of choice for patients who are at higher risk of developing severe complications as well as those who may need a heart transplant.34,35 There have been reports of modest
improvement in LVEF after bariatric surgery in patients with HF, which in some cases obviated the need for cardiac transplantation.\textsuperscript{10–12,15,16} There is, however, to the best of our knowledge, no previous report of LVEF normalization after bariatric surgery in patients with obesity and severe HF requiring LVAD therapy.

In conclusion, these two patients represent a subgroup of patients with severe HF and obesity, whose heart function can be significantly improved after bariatric surgery and LVAD support without the need for cardiac transplantation. These findings could potentially favour more aggressive use of bariatric surgery for these critically ill patients. Factors predicting potential HF reversibility and normalization of LVEF in patients with obesity-related severe HF are currently unknown, and further studies are needed to identify them.

Acknowledgements

The authors acknowledge the editorial services of Michelle Sauer, PhD, ELS.

Conflict of interest

None declared.

References

1. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity among adults and youth: United States, 2015–2016. \textit{NCHS Data Brief} 2017; 288: 1–8.

2. Rueda-Clausen CF, Ogunleye AA, Sharma AM. Health benefits of long-term weight-loss maintenance. \textit{Annu Rev Nutr} 2015; 35: 475–516.

3. Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. \textit{Lancet} 2011; 378: 815–825.

4. Dixon JB, Schachter LM, Ogunleye AA, Jones K, Grima M, Lambert G, Brown W, Bailey M, Naughton MT. Surgical vs conventional therapy for weight loss treatment of obstructive sleep apnea: a randomized controlled trial. \textit{JAMA} 2012; 308: 1142–1149.

5. Gloy VL, Briel M, Bhatt DL, Kashyap SR, Schauer PR, Schauer FR, Bionte G, Bucher HC, Nordmann AJ. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. \textit{BMJ} 2013; 347: f5934.

6. Ikramuddin S, Korner J, Lee WJ, Thomas AJ, Connell JE, Bantle JP, Leslie DB, Wang Q, Inabnet WB 3rd, Jeffery RW, Chong K, Chuang LM, Jensen MD, Vella A, Ahmed I, Belani K, Billington CJ. Lifestyle intervention and medical management vs without Roux-en-Y gastric bypass and control of hemoglobin A1c, LDL cholesterol, and systolic blood pressure at 5 years in the diabetes surgery study. \textit{JAMA} 2018; 319: 266–278.

7. Omana JJ, Nguyen SQ, Herron D, Kini S. Comparison of morbidity resolution and improvement between laparoscopic sleeve gastrectomy and laparoscopic adjustable gastric banding. \textit{Surg Endosc} 2010; 2513–2517.

8. Schauer PR, Bhatt DL, Kirwan JP, Wolksi A, Aminian A, Brethauer SA, Navaneethan SD, Singh RP, Pothier CE, Nissen SE, Kashyap S, Investigators S. Bariatric surgery versus intensive medical therapy for diabetes—5-year outcomes. \textit{N Engl J Med} 2017; 376: 641–651.

9. Sjostrom L. Review of the key results of the Swedish Obese Subjects (SOS) trial—a prospective controlled intervention study of bariatric surgery. \textit{J Intern Med} 2013; 273: 219–234.

10. Aggarwal R, Harling L, Ethimouei E, Darzi A, Athanasiou T, Ashrafian H. The effects of bariatric surgery on cardiac structure and function: a systematic review of cardiac imaging outcomes. \textit{Obes Surg} 2016; 26: 1030–1040.

11. Kindel TL, Strande JL. Bariatric surgery as a treatment for heart failure: review of the literature and potential mechanisms. \textit{Surg Obes Relat Dis} 2018; 14: 117–122.

12. Vest AR, Patel P, Schauer PR, Satava ME, Cavalcante JL, Brethauer S, Young JB. Clinical and echocardiographic outcomes after bariatric surgery in obese patients with left ventricular systolic dysfunction. \textit{Circ Heart Fail} 2016; 9: e002260.

13. Chaudhry UI, Kanji A, Sai-Sudhakar CB, Higgins RS, Needleman BJ. Laparoscopic sleeve gastrectomy in morbidly obese patients with end-stage heart failure and left ventricular assist device: medium-term results. \textit{Surg Obes Relat Dis} 2015; 11: 88–93.

14. Hawkins RB, Go K, Raymond SL, Ayzengart A, Friedman J. Laparoscopic sleeve gastrectomy in patients with heart failure and left ventricular assist devices as a bridge to transplant. \textit{Surg Obes Relat Dis} 2018; 14: 1269–1273.

15. Lim CP, Fisher OM, Falkenback D, Boyd D, Hayward CS, Keogh A, Samaras K, MacDonald P, Lord RV. Bariatric surgery provides a “bridge to transplant” for morbidly obese patients with advanced heart failure and may obviate the need for transplantation. \textit{Obes Surg} 2016; 26: 486–493.

16. Ramani GV, McCloskey C, Ramanathan RC, Mathier MA. Safety and efficacy of bariatric surgery in morbidly obese patients with severe systolic heart failure. \textit{Clin Cardiol} 2008; 31: 516–520.

17. Shah SK, Gregoric ID, Nathan SS, Akkant B, Bar B, Bajwa KS, Group LVSCG. Simultaneous left ventricular assist device placement and laparoscopic sleeve gastrectomy as a bridge to transplant for morbidly obese patients with severe heart failure. \textit{J Heart Lung Transplant} 2015; 34: 1489–1491.

18. Wikel KJ, McCloskey CA, Ramanathan RC. Bariatric surgery: a safe and effective conduit to cardiac transplantation. \textit{Surg Obes Relat Dis} 2014; 10: 479–484.

19. Kenealaha I, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, Kannel WB, Vasan RS. Obesity and the risk of heart failure. \textit{N Engl J Med} 2002; 347: 305–313.

20. Karmazyn M, Purdham DM, Rajapurohitam V, Zeidan A. Signalling mechanisms underlying the metabolic and other effects of adipokines on the heart. \textit{Cardiovasc Res} 2008; 79: 279–286.

21. Cavalera M, Wang J, Frangogiannis NG. Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities. \textit{Transl Res} 2014; 164: 323–335.

22. de Simone G, Palmieri V, Bella JN, Celentano A, Hong Y, Oberman A.
Kitzman DW, Hopkins PN, Arnett DK, Devereux RB. Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study. *J Hypertens* 2002; 20: 323–331.

23. McGill HC Jr, McMahan CA, Herderick EE, Zieske AW, Malcom GT, Tracy RE, Strong JP. Pathobiological Determinants of Atherosclerosis in Youth Research G. Obesity accelerates the progression of coronary atherosclerosis in young men. *Circulation* 2002; 105: 2712–2718.

24. Cozzolino D, Grandone A, Cittadini A, Palmiero G, Esposito G, De Bellis A, Furlan R, Perrotta S, Perrone L, Torella D, Miraglia Del Giudice E. Subclinical myocardial dysfunction and cardiac autonomic dysregulation are closely associated in obese children and adolescents: the potential role of insulin resistance. *PLoS ONE* 2015; 10: e0123916.

25. Horwich TB, Fonarow GC. Glucose, obesity, metabolic syndrome, and diabetes relevance to incidence of heart failure. *J Am Coll Cardiol* 2010; 55: 283–293.

26. Jean-Louis G, Zizi F, Clark JT, Brown CD, McFarlane SL. Obstructive sleep apnea and cardiovascular disease: role of the metabolic syndrome and its components. *J Clin Sleep Med* 2008; 4: 261–272.

27. Backman L, Freysschuss U, Hallberg D, Melcher A. Reversibility of cardiovascular changes in extreme obesity. Effects of weight reduction through jejunileostomy. *Acta Med Scand* 1979; 205: 367–373.

28. Owlen T, Avelar E, Morley K, Jiji R, Hall N, Krezowski J, Gallagher J, Williams Z, Preece K, Gundersen N, Strong MB, Pendleton RC, Segerson N, Cloward TV, Walker JM, Farney RJ, Gress RE, Adams TD, Hunt SC, Litwin SE. Favorable changes in cardiac geometry and function following gastric bypass surgery: 2-year follow-up in the Utah obesity study. *J Am Coll Cardiol* 2011; 57: 732–739.

29. Vest AR, Heneghan HM, Agarwal S, Schauer PR, Young JB. Bariatric surgery and cardiovascular outcomes: a systematic review. *Heart* 2012; 98: 1763–1777.

30. Carlin AM, Zeni TM, English WJ, Hawasi AA, Genaw JA, Krause KR, Schram JL, Kole KI, Finks JF, Birkmeyer JD, Share D, Birkmeyer NJ, Michigan Bariatric Surgery C. The comparative effectiveness of sleeve gastrectomy, gastric bypass, and adjustable gastric banding procedures for the treatment of morbid obesity. *Ann Surg* 2013; 257: 791–797.

31. Hutter MM, Schirmer BD, Jones DB, Ko CY, Cohen ME, Merkow RP, Nguyen NT. First report from the American College of Surgeons Bariatric Surgery Center Network: laparoscopic sleeve gastrectomy has morbidity and effectiveness positioned between the band and the bypass. *Ann Surg* 2011; 254: 410–420; discussion 420–412.

32. Lager CJ, Esfandiari NH, Subauste AR, Kraftson AT, Brown MB, Cassidy RB, Nay CK, Lockwood AL, Varban OA, Oral EA. Roux-En-Y gastric bypass vs. sleeve gastrectomy: balancing the risks of surgery with the benefits of weight loss. *Obes Surg* 2017; 27: 154–161.

33. Sucandy I, Titano J, Bonanni F, Antanavicius G. Comparison of vertical sleeve gastrectomy versus biliopancreatic diversion. *N Am J Med Sci* 2014; 6: 35–38.

34. Kim SH, Son SY, Park YS, Ahn SH, Park DJ, Kim HH. Risk factors for anastomotic leakage: a retrospective cohort study in a single gastric surgical unit. *J Gastric Cancer* 2015; 15: 167–175.

35. Strong AT, Sharma G, Tu C, Aminian A, Young JB, Rodriguez J, Kroh M. A population-based study of early postoperative outcomes in patients with heart failure undergoing bariatric surgery. *Obes Surg* 2018; 28: 2281–2288.